Bausch Health reports $49M Q3 loss, raises full-year financial guidance

LAVAL, Que. — Bausch Health Companies Inc. raised its profit and revenue guidance as it reported a US$49-million loss in its latest quarter.

The drug company, which keeps its books in U.S. dollars, says it now expects full-year revenue in a range from $8.475 and $8.625 billion, up from earlier expectations for revenue between $8.40 billion to $8.60 billion.

Full-year adjusted earnings before interest, taxes, depreciation and amortization are expected to be in a range from $3.50 billion to $3.60 billion compared with earlier guidance for between $3.425 billion to $3.575 billion.

The company says the loss amounted to 14 cents per share for the quarter compared with a loss of $350 million or $1.00 per share in the same quarter last year.

On an adjusted basis, Bausch earned net income of $425 million in the quarter compared with $403 million for the third quarter of 2018.

Revenue totalled nearly $2.21 billion, up from nearly $2.14 billion a year ago.

This report by The Canadian Press was first published Nov. 4, 2019.

Companies in this story: (TSX:BHC)



The Canadian Press

Note to readers: This is a corrected story. An earlier version incorrectly stated the company’s revised guidance.